IIT Kanpur licensed the technology to Reliance Life Sciences Pvt. Ltd. and this marks the first time a gene therapy related technology has been developed and transferred from an academic institution to a company in India.
Cases and Conversations™: New Treatment Strategies for nAMD & DME
07/28/2023
View More
Community Practice Connections™: Inflammation & Pathogenesis in DME – Rethinking the Traditional Treatment Paradigm
View More
Ophthalmology Consultations™: Keeping an Eye Out for MGD-Associated Dry Eye in Pre/Post-Op Patients – Improving Surgical Outcomes by Optimizing the Surface
View More
(COPE Credit) Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium
View More
Comprehensive Key Advances in Biosimilars for Retinal Diseases – Reviewing the Evidence, Addressing Patient Perspectives, and Practice Utilization for the Retina Specialist
View More
Cases & Conversations™: Inflammation & Pathogenesis in DME – Rethinking the Traditional Treatment Paradigm
View More
(CME Credit) Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium
View More
(COPE Credit) Expert Illustrations & Commentaries™: Visualizing the Angiopoetin-Tie2 Pathway as a Target in Retinal and Choroidal Vascular Diseases
View More
Alkeus announces funding and the appointment of Joshua Boger to executive chairman
June 7th 2023The $150 Million Series B funding will allow for the registration and launch of gilderuretinol, the first and only medicine in clinical development to address the underlying mechanism of Stargardt disease.
For LGBTQ+ ophthalmologists, truth has often had consequences
For Michael A. Puente Jr., MD, being open about himself and advocating for an overlooked community hasn’t always been as easy as it is today. Progress has been incremental, but he is optimistic about the state of ophthalmology for LGBTQ+ physicians and patients.